Quantcast

Latest Xeloda Stories

2010-06-08 08:05:00

Data Reported at ASCO Confirm a Statistically Significant Improvement in Both Time to Tumor Progression and Overall Survival in the Perifosine + Capecitabine Arm Versus Placebo + Capecitabine Arm QUEBEC CITY, June 8 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the "Company"), a late-stage drug development company specialized in oncology and endocrine therapy, today reported final results on the clinical activity of perifosine (KRX-0401), the Company's novel,...

2010-04-08 07:35:00

Phase 3 X-PECT Trial (Xeloda(R)) + Perifosine Evaluation in Colorectal Cancer Treatment) being conducted by partner Keryx Biopharmaceuticals pursuant to Special Protocol Assessment with the Food and Drug Administration QUEBEC CITY, April 8 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the "Company"), a late-stage drug development company specialized in oncology and endocrine therapy, today announced the initiation of a Phase 3 registration clinical trial with...

2010-02-03 07:35:00

Phase 3 X-PECT Trial (Xeloda(R) + Perifosine Evaluation in Colorectal cancer Treatment) to be led by Dr. Johanna Bendell, Director, GI Oncology Research, Sarah Cannon Research Institute QUEBEC CITY, Feb. 3 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (Nasdaq: AEZS; TSX: AEZ) (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that its partner, Keryx Biopharmaceuticals (Nasdaq: KERX), has reached an agreement with the U.S. Food...

2010-02-01 08:26:00

WALTHAM, Mass., Feb. 1 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the second-line treatment of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer, a targeted treatment that increases the median progression-free survival relative to a regimen of GlaxoSmithKline/Nippon Kayaku's Tykerb/Tyverb and Roche/Chugai's Xeloda would earn similar patient share in the...

2010-01-25 07:35:00

Data Reported at the 2010 ASCO GI Cancers Symposium Demonstrate a Statistically Significant Improvement in Both Time to Tumor Progression and Overall Survival in the Perifosine + Capecitabine Arm Versus Placebo + Capecitabine Arm QUEBEC CITY, Jan. 25 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (Nasdaq: AEZS; TSX: AEZ) (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that its partner, Keryx Biopharmaceuticals (Nasdaq: KERX),...

aad3ecfe80001999b63c54aa94f3e60d1
2009-05-27 13:45:20

The United States immigration said that a cancer patient from Singapore who traveled to the U.S. last year had missing fingerprints, which was determined to be an unusual side effect of his medication, The Associated Press reported. Authorities said the 62-year-old man, identified only as Mr. S, had been taking the medication capecitabine, or Xeloda, to treat head and neck cancer. Immigration officials asked him for his fingerprints once he arrived in the country and found that he no longer...

2009-04-14 07:00:00

Expects to qualify for 180 days of sole marketing exclusivity PITTSBURGH, April 14 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today confirmed that the company and its subsidiary Mylan Pharmaceuticals Inc. have been sued by Hoffmann-La Roche Inc. in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Capecitabine Tablets, 150 mg and 500 mg, the generic version of Xeloda(R) Tablets, a chemotherapy treatment for...

2009-01-13 17:00:00

-Growing Body of Data Supports XELOX as Effective Alternative to Standard of Care- NUTLEY, N.J., Jan. 13 /PRNewswire-FirstCall/ -- Overall survival results from a 14-month follow-up of the international, Phase III NO16966 study confirm that oral Xeloda(R) plus oxaliplatin (XELOX) is comparable to a current standard treatment, FOLFOX-4 (infused 5-FU/leucovorin plus oxaliplatin) in the first-line treatment of advanced (metastatic) colorectal cancer. In the study, patients receiving XELOX...

2008-12-09 06:00:00

NUTLEY, N.J., Dec. 9 /PRNewswire/ -- Roche announced today that a total of 20 U.S. and global abstracts involving its oral chemotherapy Xeloda(R) (capecitabine) have been accepted for presentation at the 2008 San Antonio Breast Cancer Symposium (SABCS) in San AntonioDecember 12-14, including a late-breaking study in early breast cancer to be presented on Sunday, December 14, by the Finnish Breast Cancer Group. Two U.S. abstracts to be presented at the meeting compare the impact of...


Word of the Day
tessitura
  • The prevailing range of a vocal or instrumental part, within which most of the tones lie.
This word is Italian in origin and comes from the Latin 'textura,' web, structure.